Business
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurementFDA Breakthrough Therapy Designation is
About this update from Biogen Inc.
[{"type":"image","alt":"Biogen Inc.","displaySize":"","headline":null,"caption":"Biogen Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/d780d0e9a7ba00777730acf271f9e937"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wH5zYbm3mC0cXQRHhCXgVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d780d0e9a7ba00777730acf271f9e937","width":300,"height":101}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity","length":193,"tagName":"p"}]},{"val":[{"type":"text","content":"Litifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurement","length":267,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA Breakthrough Therapy Designation is granted to expedite the development and review of drugs for serious diseases","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":576,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2). CLE is a chronic autoimmune disease affecting the skin that currently has no targeted treatments.","length":496,"tagName":"p"},{"type":"text","content":""The breakthrough therapy designation for litifilimab illustrates the FDA’s recognition of cutaneous lupus as a serious disease that urgently requires new therapies," said Victoria Werth, MD, MS, a professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania, and one of the researchers who is conducting the phase 3 trial. "With topical steroids and antimalarials as the initial therapies&nbs...